19 / 21
Page 78
conferenceseries
.com
Volume 8
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Dementia 2018
October 29-31, 2018
October 29-31, 2018 | Valencia, Spain
12
th
International Conference on
Alzheimer’s Disease & Dementia
Intranasal insulin attenuate signs of Alzheimer’s disease following chronic hypoxia
Simin Mahakizadeh
Tehran University of Medical Sciences, Iran
A
lzheimer’s disease (AD) is a metabolic neurodegenerative disease featured by cerebrovascular dysfunction in addition to
cognitive decline. Amyloid β (Aβ) plaques followed by up-regulation of amyloid precursor protein (APP) and seladin-1
down-regulation, as well as insulin signaling impairment are associated with this disease. This study was designed to evaluate
the effect of insulin on Alzheimer’s signs induced by chronic hypoxia. 24 male rats were randomly divided into four groups:
control (C), sham (Sh), hypoxia (H), hypoxia + insulin (HI) and were exposed to hypoxic chamber (8% O2, 92% N2) for 30
days (four hours/day) in H and HI groups. Pro-inflammatory cytokines and insulin receptor substrate (IRS-1) in sera were
measured on day 30 after hypoxia period. Intranasal insulin administration was used as a neuroprotective and antidiabetic
drug. Spatial learning and memory were analyzed using the Morris water maze task. Amyloid precursor protein gene (APP)
and seladin-1 gene expression were studied in the hippocampus by real time-PCR. TNF-α, IL-1β and IRS-1 had significant
magnification in H group compared with C and Sh groups (p<0.05). Insulin improved Alzheimer’s signs such as seladin-1
fallen, APP risen gene expression and memory impairment. In conclusion, we indicate that chronic hypoxia mediates AD
pathogenesis and using insulin hormone as a neuroprotective and antidiabetic drug could be beneficial in neurodegenerative
damage induced by hypoxia.
Si.mahakizadeh@gmail.comJ Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C7-055